CL2023003794A1 - Agonista del receptor de glp-1 y composición y uso del mismo - Google Patents
Agonista del receptor de glp-1 y composición y uso del mismoInfo
- Publication number
- CL2023003794A1 CL2023003794A1 CL2023003794A CL2023003794A CL2023003794A1 CL 2023003794 A1 CL2023003794 A1 CL 2023003794A1 CL 2023003794 A CL2023003794 A CL 2023003794A CL 2023003794 A CL2023003794 A CL 2023003794A CL 2023003794 A1 CL2023003794 A1 CL 2023003794A1
- Authority
- CL
- Chile
- Prior art keywords
- glp
- composition
- receptor agonist
- receptor
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110702643 | 2021-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023003794A1 true CL2023003794A1 (es) | 2024-05-24 |
Family
ID=84544137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023003794A CL2023003794A1 (es) | 2021-06-24 | 2023-12-19 | Agonista del receptor de glp-1 y composición y uso del mismo |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11981666B2 (https=) |
| EP (1) | EP4361145A4 (https=) |
| JP (1) | JP2024523525A (https=) |
| KR (1) | KR20240024910A (https=) |
| CN (2) | CN117098758A (https=) |
| AU (1) | AU2022300055A1 (https=) |
| CA (1) | CA3219984A1 (https=) |
| CL (1) | CL2023003794A1 (https=) |
| CO (1) | CO2023017726A2 (https=) |
| CR (1) | CR20230611A (https=) |
| DO (1) | DOP2023000275A (https=) |
| EC (1) | ECSP23095307A (https=) |
| IL (1) | IL309235A (https=) |
| MX (1) | MX2023014985A (https=) |
| PE (1) | PE20241794A1 (https=) |
| TW (1) | TW202317553A (https=) |
| WO (1) | WO2022268152A1 (https=) |
| ZA (1) | ZA202400786B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3157525A1 (en) | 2019-10-25 | 2021-04-29 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| PH12023552860A1 (en) | 2021-04-21 | 2024-05-20 | Gilead Sciences Inc | Carboxy-benzimidazole glp-1r modulating compounds |
| IL310377A (en) | 2021-08-30 | 2024-03-01 | Mindrank Ai Ltd | Novel aryl ether substituted heterocyclic compound as glp1r agonist |
| KR20240068737A (ko) | 2021-09-27 | 2024-05-17 | 테른스 파마슈티칼스, 인크. | Glp-1r 효능제로서의 벤즈이미다졸 카복실산 |
| AU2022375634A1 (en) | 2021-10-25 | 2024-06-06 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| KR20240150488A (ko) | 2022-02-23 | 2024-10-15 | 테른스 파마슈티칼스, 인크. | Glp-1r 작용제로서의 화합물 |
| US20260097037A1 (en) | 2022-09-22 | 2026-04-09 | Shionogi & Co., Ltd. | Fused ring compound having glp-1 receptor agonist effect |
| CN120530106A (zh) * | 2022-12-13 | 2025-08-22 | 杭州中美华东制药有限公司 | Glp-1受体激动剂的新晶型和制备方法及其药物组合物和用途 |
| TW202440556A (zh) * | 2022-12-13 | 2024-10-16 | 中國大陸商杭州中美華東製藥有限公司 | 鹽型的glp-1受體激動劑、其晶型和製備方法及其藥物組合物和用途 |
| CN118496200A (zh) * | 2023-02-14 | 2024-08-16 | 成都康弘药业集团股份有限公司 | 吲唑啉酮类化合物及其制备方法和用途 |
| US20240398794A1 (en) | 2023-04-07 | 2024-12-05 | Terns Pharmaceuticals, Inc. | COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF |
| TW202504600A (zh) | 2023-07-04 | 2025-02-01 | 大陸商杭州中美華東製藥有限公司 | Glp1r激動劑及其中間體的製備方法 |
| TW202521533A (zh) | 2023-09-14 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
| WO2025252098A1 (zh) * | 2024-06-05 | 2025-12-11 | 杭州中美华东制药有限公司 | Glp-1受体激动剂的口服药物组合物及其制备方法 |
| KR20260032385A (ko) * | 2024-08-28 | 2026-03-09 | 주식회사유한양행 | Glp-1 수용체 효능제 활성을 가진 시에노이미다졸 화합물, 이의 제조 방법, 및 이들의 의약 용도 |
| CN119837849B (zh) * | 2025-02-10 | 2025-06-13 | 中国科学院北京基因组研究所(国家生物信息中心) | 蜡菊素在制备缓解和治疗受试者细胞红系分化障碍的药物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7727983B2 (en) | 2008-03-07 | 2010-06-01 | Transtech Pharma, Inc. | Oxadiazoanthracene compounds for the treatment of diabetes |
| JP5755217B2 (ja) | 2009-03-30 | 2015-07-29 | トランステック・ファーマ，エルエルシー | 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法 |
| US10723699B2 (en) | 2015-11-04 | 2020-07-28 | Hyundai Pharm Co., Ltd. | Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient |
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| EP3555064B9 (en) | 2016-12-16 | 2023-03-01 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| KR101910586B1 (ko) | 2017-03-03 | 2018-10-23 | 한국화학연구원 | 헤테로아릴이 치환된 2-페닐이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 GLP-1 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| CR20210341A (es) * | 2018-11-22 | 2021-11-25 | Qilu Regor Therapeutics Inc | Agonistas de glp-ir y usos de los mismos |
| AU2020256647B2 (en) * | 2019-04-12 | 2025-07-31 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| WO2021018023A1 (zh) * | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | 小分子glp-1受体调节剂 |
| CA3157525A1 (en) * | 2019-10-25 | 2021-04-29 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| WO2021160127A1 (en) * | 2020-02-13 | 2021-08-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2022068772A1 (zh) * | 2020-09-29 | 2022-04-07 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| EP4247804A1 (en) * | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| WO2022225914A1 (en) * | 2021-04-21 | 2022-10-27 | Gilead Sciences, Inc. | Carboxy-benzimidazole glp-1r modulating compounds |
-
2022
- 2022-06-23 WO PCT/CN2022/100685 patent/WO2022268152A1/zh not_active Ceased
- 2022-06-23 CN CN202280018027.6A patent/CN117098758A/zh active Pending
- 2022-06-23 EP EP22827644.0A patent/EP4361145A4/en active Pending
- 2022-06-23 AU AU2022300055A patent/AU2022300055A1/en active Pending
- 2022-06-23 JP JP2023579274A patent/JP2024523525A/ja active Pending
- 2022-06-23 PE PE2023003275A patent/PE20241794A1/es unknown
- 2022-06-23 CR CR20230611A patent/CR20230611A/es unknown
- 2022-06-23 CA CA3219984A patent/CA3219984A1/en active Pending
- 2022-06-23 KR KR1020247001274A patent/KR20240024910A/ko active Pending
- 2022-06-23 TW TW111123462A patent/TW202317553A/zh unknown
- 2022-06-23 MX MX2023014985A patent/MX2023014985A/es unknown
- 2022-06-23 CN CN202311318579.1A patent/CN117362283B/zh active Active
- 2022-06-23 IL IL309235A patent/IL309235A/en unknown
-
2023
- 2023-09-13 US US18/367,517 patent/US11981666B2/en active Active
- 2023-12-14 DO DO2023000275A patent/DOP2023000275A/es unknown
- 2023-12-18 CO CONC2023/0017726A patent/CO2023017726A2/es unknown
- 2023-12-19 CL CL2023003794A patent/CL2023003794A1/es unknown
- 2023-12-19 EC ECSENADI202395307A patent/ECSP23095307A/es unknown
-
2024
- 2024-01-23 ZA ZA2024/00786A patent/ZA202400786B/en unknown
- 2024-03-22 US US18/613,714 patent/US20240360110A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022268152A1 (zh) | 2022-12-29 |
| AU2022300055A1 (en) | 2024-01-18 |
| CN117362283A (zh) | 2024-01-09 |
| US11981666B2 (en) | 2024-05-14 |
| US20240360110A1 (en) | 2024-10-31 |
| US20240116906A1 (en) | 2024-04-11 |
| CN117362283B (zh) | 2024-07-09 |
| CR20230611A (es) | 2024-02-19 |
| EP4361145A1 (en) | 2024-05-01 |
| JP2024523525A (ja) | 2024-06-28 |
| PE20241794A1 (es) | 2024-09-06 |
| ECSP23095307A (es) | 2024-01-31 |
| KR20240024910A (ko) | 2024-02-26 |
| TW202317553A (zh) | 2023-05-01 |
| EP4361145A4 (en) | 2025-05-21 |
| MX2023014985A (es) | 2024-02-14 |
| CO2023017726A2 (es) | 2024-02-15 |
| IL309235A (en) | 2024-02-01 |
| DOP2023000275A (es) | 2024-02-15 |
| CN117098758A (zh) | 2023-11-21 |
| ZA202400786B (en) | 2024-10-30 |
| CA3219984A1 (en) | 2022-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023003794A1 (es) | Agonista del receptor de glp-1 y composición y uso del mismo | |
| UY38958A (es) | Agonista del receptor glp-1 y uso de este | |
| MX2021007576A (es) | Nuevo anticuerpo anti receptor 8 de motivo c-c de quimiocina (ccr8). | |
| CO2021017401A2 (es) | Agonistas de receptor de melanocortina-4 | |
| PE20191474A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer | |
| PE20220590A1 (es) | Agonistas del receptor del peptido-1 similar al glucagon | |
| CO2019005924A2 (es) | Agonistas duales acilados de glp-1/glp-2 | |
| MX2021002180A (es) | Composiciones de inhibidores del receptor de quimiocina c-x-c tipo 4 (cxcr4) y metodos de preparacion y uso. | |
| MX2021013817A (es) | Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer. | |
| ES3061179T3 (en) | Incretin analogs and uses thereof | |
| MX2017004906A (es) | Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma. | |
| MX2024003236A (es) | Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos. | |
| DOP2018000297A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
| UY37098A (es) | Moduladores de ror-gamma | |
| DOP2025000199A (es) | Agonistas heterocíclicos de glp-1 | |
| MX2016012368A (es) | Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r). | |
| CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
| MX373268B (es) | Compuestos ppar para uso en el tratamiento de enfermedades fibroticas. | |
| CL2019003325A1 (es) | Uso novedoso de un agonista del receptor 2 de formil péptido / receptor a4de lipoxina (fpr2 / alx) para el tratamiento de la insuficiencia cardíaca. | |
| NI201500175A (es) | Compuestos nuevos para el tratamiento del cáncer | |
| MX2021014357A (es) | Metodos y formulaciones para tratar trastornos de la vision. | |
| MX2020003185A (es) | Nuevos compuestos heterociclicos. | |
| MX2024002581A (es) | Lou064 para el tratamiento de la esclerosis multiple. | |
| CL2024000881A1 (es) | Estructuras derivadas de tn3 específicas de cd40l para tratamiento y prevención del síndrome de sjogren | |
| CO2021001925A2 (es) | Piridopirimidinas como inhibidores del receptor de histamina h4 |